Lexeo Therapeutics (LXEO) Competitors $4.79 +0.03 (+0.63%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$4.80 +0.01 (+0.21%) As of 08/29/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXEO vs. SYRE, PRAX, CRMD, CRON, NUVB, VERV, VALN, MLYS, ATAI, and IOVAShould you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Spyre Therapeutics (SYRE), Praxis Precision Medicines (PRAX), CorMedix (CRMD), Cronos Group (CRON), Nuvation Bio (NUVB), Verve Therapeutics (VERV), Valneva (VALN), Mineralys Therapeutics (MLYS), atai Life Sciences (ATAI), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry. Lexeo Therapeutics vs. Its Competitors Spyre Therapeutics Praxis Precision Medicines CorMedix Cronos Group Nuvation Bio Verve Therapeutics Valneva Mineralys Therapeutics atai Life Sciences Iovance Biotherapeutics Lexeo Therapeutics (NASDAQ:LXEO) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Is LXEO or SYRE more profitable? Spyre Therapeutics' return on equity of -71.30% beat Lexeo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lexeo TherapeuticsN/A -94.65% -73.36% Spyre Therapeutics N/A -71.30%-38.69% Do insiders & institutionals believe in LXEO or SYRE? 60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 5.3% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 15.4% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, LXEO or SYRE? Lexeo Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.87, indicating that its share price is 187% more volatile than the S&P 500. Do analysts prefer LXEO or SYRE? Lexeo Therapeutics presently has a consensus target price of $15.33, indicating a potential upside of 220.11%. Spyre Therapeutics has a consensus target price of $53.40, indicating a potential upside of 223.83%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spyre Therapeutics is more favorable than Lexeo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has preferable earnings & valuation, LXEO or SYRE? Lexeo Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexeo Therapeutics$650K397.94-$98.33M-$3.26-1.47Spyre TherapeuticsN/AN/A-$208.02M-$3.40-4.85 Does the media favor LXEO or SYRE? In the previous week, Spyre Therapeutics had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 7 mentions for Spyre Therapeutics and 5 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.28 beat Spyre Therapeutics' score of 1.19 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive SummarySpyre Therapeutics beats Lexeo Therapeutics on 9 of the 15 factors compared between the two stocks. Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXEO vs. The Competition Export to ExcelMetricLexeo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$258.66M$2.49B$5.69B$9.74BDividend YieldN/A48.55%6.64%4.48%P/E Ratio-1.4722.8083.1926.59Price / Sales397.94544.56515.16159.07Price / CashN/A26.3325.6628.92Price / Book1.365.3711.766.08Net Income-$98.33M$32.95M$3.27B$265.93M7 Day Performance2.79%-0.65%1.13%0.36%1 Month Performance3.90%6.46%8.30%5.58%1 Year Performance-58.38%-3.15%62.26%19.67% Lexeo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXEOLexeo Therapeutics2.4343 of 5 stars$4.79+0.6%$15.33+220.1%-58.4%$258.66M$650K-1.4758Positive NewsSYRESpyre Therapeutics2.9711 of 5 stars$16.58-4.6%$53.40+222.1%-42.6%$1.05BN/A-4.8873News CoveragePositive NewsAnalyst DowngradePRAXPraxis Precision Medicines1.6672 of 5 stars$46.94-3.8%$85.88+82.9%-14.3%$1.03B$8.55M-3.82110CRMDCorMedix2.6823 of 5 stars$13.73+0.3%$16.71+21.7%+137.7%$1.02B$43.47M18.3130News CoveragePositive NewsCRONCronos Group1.7183 of 5 stars$2.60-0.2%N/A+15.0%$995.90M$117.61M51.90450Analyst UpgradeNUVBNuvation Bio2.2774 of 5 stars$2.88-0.7%$7.33+154.6%-7.6%$992.59M$7.87M-4.5760VERVVerve Therapeutics1.984 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110VALNValneva1.7931 of 5 stars$9.43-19.0%$16.00+69.7%+20.9%$990.49M$183.52M-9.62700Gap UpHigh Trading VolumeMLYSMineralys Therapeutics3.0371 of 5 stars$14.74-1.0%$32.25+118.8%+24.7%$986.80MN/A-4.1428News CoveragePositive NewsATAIatai Life Sciences3.3609 of 5 stars$4.74+3.7%$11.25+137.3%+252.3%$979.53M$310K-6.8780Gap UpHigh Trading VolumeIOVAIovance Biotherapeutics4.6878 of 5 stars$2.53-5.9%$11.90+370.4%-80.9%$973.39M$164.07M-2.06500 Related Companies and Tools Related Companies Spyre Therapeutics Competitors Praxis Precision Medicines Competitors CorMedix Competitors Cronos Group Competitors Nuvation Bio Competitors Verve Therapeutics Competitors Valneva Competitors Mineralys Therapeutics Competitors atai Life Sciences Competitors Iovance Biotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LXEO) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LXEO Stock Alerts